Jasper Therapeutics (JSPR) Non-Current Deferred Tax Liability (2020 - 2023)

Jasper Therapeutics has reported Non-Current Deferred Tax Liability for 4 years, with the latest figure at $488000.0 in Q4 2023.

• On a quarterly basis, Non-Current Deferred Tax Liability fell 13.32% year-over-year to $488000.0 in Q4 2023; TTM through Dec 2023 was $488000.0, a 13.32% decrease from a year earlier, with the FY2023 full-year figure at $488000.0, down 13.32% from the prior year.
• Non-Current Deferred Tax Liability was $488000.0 for Q4 2023 at Jasper Therapeutics, down from $563000.0 in the prior quarter.
• The five-year high for Non-Current Deferred Tax Liability was $563000.0 in Q4 2022, with the low at $323000.0 in Q4 2021.
• Average Non-Current Deferred Tax Liability over 4 years is $443250.0, with a median of $443500.0 recorded in 2020.
• The sharpest annual moves came in 2021 and 2022: Non-Current Deferred Tax Liability retreated 19.05% in 2021, then surged 74.3% in 2022.
• Over 4 years, Non-Current Deferred Tax Liability stood at $399000.0 in 2020, then declined by 19.05% to $323000.0 in 2021, then jumped by 74.3% to $563000.0 in 2022, then dropped by 13.32% to $488000.0 in 2023.
• The last three Non-Current Deferred Tax Liability figures came in at $488000.0 (Q4 2023), $563000.0 (Q4 2022), and $323000.0 (Q4 2021), per Business Quant data.